Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

07/23/2012 | 05:04am US/Eastern

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
Latest news
Date Title
<1m ago RESEARCH AND MARKETS : European Refrigerators And Freezers Market Report 2014
1m ago AVENIR TELECOM : Tunisia: Day 8 results in football league
1m ago DIAGEO : Correction - Diageo's Meta Abo to double its production capacity in a few months
1m ago TWENTYFOUR INCOME FUND : Directors' Dealings
2m ago DIGITAL DOMAIN : 3.0 CEO SEAH Ang Promoted to Executive Director and CEO of Digital Domain Holdings Limited
2m ago RESEARCH AND MARKETS : European Cement Market Analysis and Forecasts 2014-2020
3m ago UTILICO INVESTMENTS : Dividend Q1 2014/2015
3m ago SANOMA : Co-operation negotiations concerning Sanoma Media Finland’s telesales and customer service operations concluded
3m ago SYNERGY HEALTHCARE : Form 8.3 - Synergy Healthcare Plc
3m ago ATLANTIC GRUPA DD : Best in Its Relations with Investors
Latest news
Advertisement
Hot News 
PRESIDENT ENERGY : Oil Discovery in Paraguayan Chaco
NUTRECO : SHV and Nutreco announce a recommended cash offer of EUR 40 per share for all shares of Nutreco
ZAYO GROU : Group Holdings, Inc. Prices Initial Public Offering of Common Stock
XEROS TECHNOLOGY : Further incentive programmes from us
LOK'N STORE : Lok'nStore Profit Hit By Impairment, Signals Confidence With Dividend Hike
Most Read News
2h ago Pilots extend Lufthansa strikes to long-haul flights
2h ago Adidas shares jump on report of bid for Reebok unit
1d agoDJENERGY DEVELOPMENT : Secures $315 Million Financing For Wind Project
1d ago MICROSOFT PLANS TO LAUNCH SMARTWATCH WITHIN WEEKS : Forbes
1d ago BUSINESS MACHINES : IBM to pay Globalfoundries $1.5 billion to take chip unit off its hands - WSJ
Most recommended articles
11m ago Britain targets 2017 for start of European carbon market reforms
16m agoDJNew Libor Administration Plan Detailed
24m agoDJBNP PARIBAS : Italy Launches New Inflation-Linked Bond
25m agoDJEUROPE MARKETS : The European Selloff Is Back: Germany's DAX Stumbles 1%
30m agoDJCHINA MOBILE : Jan-Sep Net Profit Down 9.7%; Stiff Competition
Dynamic quotes  
ON
| OFF